Zymenex A/S (Hilleroed, Denmark) (including the subsidiary Zymenex AB, Lidingo, Sweden) was a biopharmaceutical company focused on the development of novel enzyme replacement therapies for the treatment of Lysosomal Storage Diseases. 

In 2008, the company’s lead product, Metazym for the treatment of Metachromatic Leukodystrophy (MLD), was acquired by Shire Pharmaceuticals for USD 135 million.

Subsequently, the company developed two new enzyme replacement therapies: Lamazym for the treatment of Alpha-mannosidosis and Galaczym for the treatment of Krabbe’s disease.

In 2013, when the Lamazym clinical phase III trial had completed enrollment of patients, Zymenex was acquired by Chiesi Farmaceutici. The financial terms of the transaction were not disclosed.

Lamazym, now named Lamzede® (velmanase alfa), was granted marketing authorisation by the European Medicines Agency (EMA) in 2018, and is now approved for use in the 31 European countries covered by the EMA.

For more information, please contact:

Sten Verland, PhD MSc

General Partner

Phone +45 2422 1969